AstraZeneca announces that a phase III trial (PACIFIC-2) of Imfinzi (durvalumab) + chemoradiotherapy (CRT) failed to meet its primary endpoint of progression-free survival (PFS) versus CRT alone, for the treatment of patients with unresectable stage III non-small cell lung cancer (NSCLC).

Imfinzi, administered sequentially after platinum-based CRT, is the established global standard of care for the treatment of unresectable stage III NSCLC, based on the results of a Phase III trial (PACIFIC).

' Although the results of the PACIFIC-2 trial did not show what we had hoped for, the PACIFIC regimen remains the standard of care for patients with unresectable stage III non-small cell lung cancer. As a community, we will learn from these results to advance future research', commented Jeffrey D. Bradley, MD, Vice President of Proton Therapy and Technology Development, Penn Medicine, Philadelphia and Principal Investigator of the trial.

Copyright (c) 2023 CercleFinance.com. All rights reserved.